ReviewClinical and experimental immunology2007
C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.
Review in Clinical and experimental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 83 citations in OpenAlex.
- Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys.Orphanet journal of rare diseases · 2025Observational
- Augmentation Therapy for Alpha-1 Antitrypsin Deficiency: Patient Experiences With Self-Infusion, Home Providers, and Clinics.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin.International journal of chronic obstructive pulmonary disease · 2023Article
- Assessment of Patient Perspectives and Barriers to Self-Infusion of Augmentation Therapy for Alpha-1 Antitrypsin Deficiency During the COVID-19 Pandemic.Pulmonary therapy · 2022Article
- The Enigma of Prodromes in Hereditary Angioedema (HAE).Clinical reviews in allergy & immunology · 2021Review
- Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency.International journal of chronic obstructive pulmonary disease · 2020Review
- Otolaryngology in Critical Care.Annals of the American Thoracic Society · 2018Review
- Acquired and hereditary forms of recurrent angioedema: Update of treatment.Allergologie select · 2018Review
- Practicalities of a reduced volume formulation of a C1-INH concentrate for the treatment of hereditary angioedema: real-life experience.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2018Article
- Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.Patient preference and adherence · 2016Review
- C1 inhibitor deficiency: 2014 United Kingdom consensus document.Clinical and experimental immunology · 2015Article
- Paediatric hereditary angioedema: a survey of UK service provision and patient experience.Clinical and experimental immunology · 2014Article
- Self-administration of intravenous C1 esterase inhibitor in hereditary angioedema.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013Review
- WAO Guideline for the Management of Hereditary Angioedema.The World Allergy Organization journal · 2012Article
- Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.Immunobiology · 2012Review
- Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy.International archives of allergy and immunology · 2012Article
- New therapeutics in C1INH deficiency: a review of recent studies and advances.Current allergy and asthma reports · 2011Review
- Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies.The World Allergy Organization journal · 2011Article
- Angioedema due to C1 inhibitor deficiency in 2010.Internal and emergency medicine · 2010Review
- Management of acute attacks of hereditary angioedema: potential role of icatibant.Vascular health and risk management · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Economic and political factors have led to the increased use of home therapy programmes for patients who have traditionally been treated in hospital. Many patients with hereditary angioedema (HAE) experience intermittent severe attacks that affect their quality of life and may be life-threatening. These attacks are treated with C1-inhibitor concentrate which, for most patients, is infused at the local hospital. Home therapy programmes for HAE are currently being established. This paper reviews the extent of use of these programmes and summarizes the advantages and potential disadvantages of the concept so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.